Help if you’re losing coverage

Practical steps, costs and pastoral support for Medical Trust members whose GLP-1 coverage ends on January 1, 2027.

General information, not medical, legal or tax advice. Your prescriber decides your treatment.

The change applies to active employees and early retirees (under 65); it does not appear to apply to retirees on Medicare (who is affected).

Before January 1

  1. Talk with your prescriber now. Make a plan for 2027 before your current supply runs out:

    • continue at self-pay prices;
    • switch to a different form or product;
    • or reduce the dose gradually with support.

    Stopping suddenly isn’t the only option, and a planned approach avoids an unplanned gap. See if you decide to stop.

  2. Look at a 2027 spending account. Medical Trust annual enrollment closes in November, but if your employer offers a health FSA, ask whether you can still sign up. Health FSA, HSA and HRA money can generally pay for these medications when they’re prescribed to treat a diagnosed disease such as obesity. NovoCare Pharmacy and LillyDirect say they accept HSA and FSA cards, but some self-pay savings terms say you won’t seek reimbursement from a health care reimbursement account, so ask your account administrator first (more on HSAs and FSAs). Keep receipts.

  3. Avoid an unplanned gap. The Wegovy label says: “If 2 or more consecutive doses … are missed, reinitiate dosage escalation at a lower dosage.” A gap can mean starting over at a low dose.

  4. Ask about a final fill while you’re still covered. Check your price in the Express Scripts app or at express-scripts.com, then ask your prescriber. Plans limit quantities and refill timing; a 3-box (84-day) home-delivery supply may be possible.

  5. Get answers in writing. Call Quantum Health at 866-871-0629 (weekdays, 8:30 AM to 10 PM Eastern), then ask for the answer by email or letter. Questions worth asking:

    • If you take Wegovy because of heart disease or MASH liver disease, or Zepbound for sleep apnea: is your prescription excluded too? The letter members received lists the medicines themselves as excluded, so plan for it to be.
    • What weight-management medications remain covered, and at what cost?

If you and your prescriber decide to stop

There is no official schedule for coming off these medicines. Neither the Wegovy label nor the Zepbound label says how to stop, and Cleveland Clinic says there’s “no established one-size-fits-all protocol.”

Many doctors lower the dose step by step, the reverse of how it was started. Mayo Clinic physicians writing in American Family Physician call stepping down “a reasonable strategy to transition off therapy,” while noting “the absence of robust evidence or guidelines.” A trial comparing a gradual taper with stopping all at once is still under way.

Most people regain some weight after stopping: about 0.4 kg (nearly a pound) a month on average, in a review of 37 studies. Ask your prescriber about regular check-ins for at least a year, as England’s NICE recommends.

If you have type 2 diabetes, your blood sugar may rise after stopping, so plan for that with your prescriber too. Don’t lower or space out your doses on your own.

What self-pay costs (manufacturer prices, October 2026)

Product Price Notes
Wegovy pens (NovoCare Pharmacy) $349 per 28-day box Same price at every dose up to 2.4 mg; Wegovy HD (7.2 mg) is $399
Wegovy pill 1.5 mg: $149
4 mg: $199
9 or 25 mg: $299
Prices are per month
Zepbound (LillyDirect) 2.5 mg: $299
5 mg: $399
7.5–15 mg: $449
Prices are per month. The $449 price requires refilling within 45 days; late refills cost more
Novo Nordisk 12-month subscription through partner telehealth services $249 a month The telehealth company’s own membership or program fee is extra

If you use the Wegovy savings card now, its copay discount ends on January 1, because that discount needs insurance that covers Wegovy. After that, the same card gets you the prices above at a participating pharmacy, or you can order from NovoCare Pharmacy. For one person on a maintenance dose, self-pay comes to roughly $3,600–$5,800 a year.

Prices change; check the manufacturer’s site on the day you buy. TrumpRx.gov lists the same manufacturer prices. Neither manufacturer’s patient-assistance program lists these medicines, and both exclude people with commercial insurance. Self-pay spending doesn’t count toward your Medical Trust deductible or out-of-pocket maximum.

What about Ozempic or Mounjaro?

Ozempic contains semaglutide, the medicine in Wegovy, and Mounjaro contains tirzepatide, the medicine in Zepbound. The FDA has approved Ozempic and Mounjaro for type 2 diabetes.

If you take one for type 2 diabetes, the Medical Trust says GLP-1 medications “will continue to be covered for type 2 diabetes treatment, subject to applicable prior authorization and utilization management requirements and other plan terms” (2027 Annual Enrollment Guide, page 5). If you take one for weight loss without type 2 diabetes, the exclusion applies to you, whatever the brand. The Church Pension Group says members who use GLP-1s “for a diagnosis other than diabetes will be responsible for the medications’ cost” (CPG Connect, September 14, 2026).

Things to be careful about

  • Compounded copies. The FDA ended the shortage-era flexibility in 2025 and has warned many sellers. If you consider one, talk with your prescriber first, and use only a state-licensed pharmacy. We don’t recommend any compounded product.
  • Diagnosis codes. Coverage must follow a genuine, documented diagnosis. Never ask a clinician to misstate one.

What the Medical Trust offers

Can I do anything about it?

You can always file an internal appeal; your plan document handbook explains how (CPG health plan documents). An exclusion usually can’t be taken to independent review, but a dispute about a use other than weight loss might be different (Can I appeal?). You can also add your name to the letter, which asks the Medical Trust for a transition and for coverage to come back in 2028.

You are not alone

Losing coverage for a treatment that is working is hard, and it can bring up shame that no one deserves. Weight is not a moral failing, and treating a chronic disease is good stewardship of the body.

If you are a priest, consider your diocesan clergy wellness resources, or someone you trust outside your parish. You care for others; let someone care for you.

Last updated

Back to top